Vertex Pharmaceuticals Inc.'s approach to cystic fibrosis (CF) – pairing the approved therapy Kalydeco (ivacaftor) as a "potentiator" with another compound, VX-661, as a "corrector" – gained market-pleasing, top-line, Phase II proof that sent the stock on a skyward ride.